By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.

Prostate Cancer surgery is not accurate enough
Prostate cancer (PCa) is the fourth most common cancer in both sexes combined and the second most common cancer in men. In Sweden PCa is the most common cancer disease among all, and 9678 men were diagnosed with PCa in 2013 (Cancerfonden). In 2012, 1.1 million men worldwide were diagnosed with prostate cancer and 307 000 estimated deaths in 2012. The most prevalent curative treatment for PCa is radical prostatectomy (RP). In Europe, RP made up 59 % of the curative treatments in 2000 and in the USA about 70 000 men were offered RP in 2003. 1880 surgical treatments for Prostate cancer is conducted per year in Sweden, 10-20 % of these need chemotherapy afterwards due to that all cancer tissue was not removed.

Our solution
A real-time instrument to increase precision that combines two sensor methods into one small probe, combining a resonance sensor with a Raman spectroscope. The Instrument can rapidly scan the prostate surface during surgery and give the surgeon correct information about correct removal of all cancer tissue.

Competitive Advantages
The instrument will during surgery give information about the localization of suspected cancer tumors by measuring the tissue hardness in prostate and define the molecular content by an optical Raman spectrum. This will give the surgeon the extra information needed to securely remove all tumor cells resulting in an efficient and more accurate removal than before. We will with our instrument reduce the risk of cancer relapse after surgical treatment that will save suffering and substantial cost.

The methods in clinical use today like ultrasound, MRI and histopathology are inexact and/or very expensive, and furthermore cannot be used during surgery, i.e. no method can give rapid information at surgical site.

Current Status
Supporting data is already provided and published and a patent is approved. A need analysis, market analysis and competition analysis supporting the idea was performed in 2006 and have to be updated.

UBI Incubation Phase


Contact Information

Tvistevägen 48C
907 36 Umeå
Olof Lindahl, Department of Radiation Sciences/Biomedical Engineering, UmU
Kerstin Ramser, Department of Engineering Sciences and Mathematics, LTU